Artiva Biotherapeutics, Inc. (ARTV)
6.66
+3.36
(+101.82%)
USD |
NASDAQ |
Dec 15, 15:22
Artiva Biotherapeutics Cash from Investing (Quarterly): 16.28M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Ovid Therapeutics, Inc. | 5.053M |
| Kezar Life Sciences, Inc. | 15.71M |
| Olema Pharmaceuticals, Inc. | 17.27M |
| Disc Medicine, Inc. | 49.54M |
| NovaBay Pharmaceuticals, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -19.20M |
| Cash from Financing (Quarterly) | -0.037M |
| Free Cash Flow | -78.90M |
| Free Cash Flow Per Share (Quarterly) | -0.8088 |
| Free Cash Flow to Equity (Quarterly) | -18.27M |
| Free Cash Flow to Firm (Quarterly) | -19.80M |
| Free Cash Flow Yield | -48.61% |